Literature DB >> 8530806

Mode of hepatitis C infection not associated with blood transfusion among chronic hemodialysis patients.

K Okuda1, H Hayashi, S Kobayashi, Y Irie.   

Abstract

In a retrospective study carried out on about 730 patients with chronic renal failure who underwent ambulatory hemodialysis from January 1991 to June 1994, 49 patients were found to have developed acute hepatitis C, as confirmed by seroconversion for anti-HCV antibodies without blood transfusion in the preceding 6-month period. Epidemiological survey disclosed that two patients undergoing dialysis at consoles separated by one console developed acute hepatitis C in October 1992, and another three patients at adjacent consoles also developed acute hepatitis C within 2 weeks in April/May, 1993. It was found that some negligent nurses could have withdrawn needles from these patients one after another without changing gloves at the termination of the dialysis procedure. After reeducation of the staff members and introduction of a new type of adhesive pad to be placed on the needle wounds at the time of needle withdrawal, no new case of acute hepatitis C occurred for more than 1 year, suggesting nosocomial spread of HCV infection among hemodialysis patients in a mode that is preventable with very strict aseptic precautions.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530806     DOI: 10.1016/0168-8278(95)80307-6

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  14 in total

1.  Remarkable difference in the mode of HCV transmission among haemodialysis patients and IVDAs.

Authors:  S M Alavian; B Hajarizadeh
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

Review 2.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

Review 3.  Nonhepatic manifestations and combined diseases in HCV infection.

Authors:  S J Hadziyannis
Journal:  Dig Dis Sci       Date:  1996-12       Impact factor: 3.199

4.  Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis.

Authors:  Ioan Sporea; Alina Popescu; Roxana Sirli; Ovidiu Golea; Camelia Totolici; Mirela Danila; Corina Vernic
Journal:  World J Gastroenterol       Date:  2006-07-14       Impact factor: 5.742

5.  Genetic and serological evidence for multiple instances of unrecognized transmission of hepatitis C virus in hemodialysis units.

Authors:  M Mizuno; T Higuchi; K Kanmatsuse; M Esumi
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

Review 6.  Hepatitis C virus screening and management of seroconversions in hemodialysis facilities.

Authors:  Chukwuma Mbaeyi; Nicola D Thompson
Journal:  Semin Dial       Date:  2013-05-31       Impact factor: 3.455

7.  Prevalence and risk factors of hepatitis C virus infection in haemodialysis patients: a multicentre study in 2796 patients.

Authors:  H Hinrichsen; G Leimenstoll; G Stegen; H Schrader; U R Fölsch; W E Schmidt
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

8.  Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4-23 years of follow-up.

Authors:  Kunio Okuda; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

9.  High incidence of hepatitis C virus infection in hemodialysis patients in units with high prevalence.

Authors:  F H Pujol; J G Ponce; M G Lema; F Capriles; M Devesa; F Sirit; M Salazar; G Vásquez; F Monsalve; L Blitz-Dorfman
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

10.  Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico.

Authors:  Nahum Méndez-Sánchez; Daniel Motola-Kuba; Norberto C Chavez-Tapia; Jesús Bahena; Ricardo Correa-Rotter; Misael Uribe
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.